1. Annual report 2023
  2. Research
  3. EMAP

EMAP

Research on Drugs in Primary Care

EMAP's main objective is to carry out research related to the use of drugs in primary care, assessing their effectiveness, efficiency and safety. We are an interdisciplinary group with experience in conducting studies using different methodologies, mainly observational studies with Real World Data and pragmatic clinical trials with medicines and medical devices. These different approaches allow for studying drugs in conditions of usual care and real life, as well as focusing on vulnerable populations such as children, pregnancy and lactation, older people, polymedicated patients,? EMAP participates in conducting independent clinical trials through SCReN platform, national infrastructure for the development of independent research, is part of SIGMA Consortium, responsible for providing scientific evidence in pharmacoepidemiology through European databases, it is especially involved in the study of drug use during pregnancy (ConcePTION) and in pharmacovigilance of COVID-19 vaccines (VAC4EU) and participates in the Pharmacotherapeutic Harmonization program of CatSalut through the Pharmacoepidemiology Technical Office, studying the use of drugs in real conditions.

Group projects

R+D+I PROJECTS FUNDED IN COMPETITIVE CALLS FROM ADMINISTRATIONS OR PUBLIC AND PRIVATE ENTITIES

  • Quality, efficacy and safety studies on medicines, Lot 5 Pharmacoepidemiological research (V. HEBRON). European Medicines Agency (EMA). 2021-2023. IP: Maria Giner Soriano.

  • Premi Trajectòria AP Rosa Morros Premis ICS 2023. ICS - Institut Català de la Salut. 2023-2024. IP: Rosa Morros Pedrós.

  • Plataforma ISCIII de soporte para la investigación clínica independiente. (PT20/00108). Instituto de Salud Carlos III. 2020-2023. IP: Rosa Morros Pedrós.

  • Plataforma Farmacovigilància (OTF). Generalitat Catalunya. Departament de Salut. 2021-2023. IP: Rosa Morros Pedrós.

CONTRACTS, AGREEMENTS OR NON-COMPETITIVE R+D+I PROJECTS WITH ADMINISTRATIONS OR PUBLIC OR PRIVATE ENTITIES.

  • Teze Cardiac PASS - SIDIAP Feasibility Questionnaire. IQVIA LTD. 2023-2024. IP: Maria Giner Soriano.

  • Smart City Observatories implement REsilient Water Management. IVL Svenska Miljöinstituten AB. 2019 IP: Rosa Morros Pedrós.

  • Oral and Neuro-Penetrative Alternative Antibiotics for Patients with Syphilis. Fundació Lluita contra la Sida. Hº Trias i Pujol. 2022-2023. IP: Rosa Morros Pedrós.

  • Assessorament i Monitorització Assaig: Evaluación de la respuesta inmune entrenada frente a la COVID-19 mediante la vacuna RUTI®: Ensayo clínico exploratorio, doble-ciego, aleatorizado, controlado con placebo. Fund.Institut Inv.Ciencies Salut Germans Trias i Pujol (IGTP). 2021 IP: Rosa Morros Pedrós.

  • Actividades de Farmacovigilancia del "ensayo clínico: Evolocumab en insuficiencia cardíaca estable con fracción de eyección reducida de etiología isquémica: EVO-FH Pilot". Fundació Lluita contra la Sida. Hº Trias i Pujol. 2019-2023. IP: Rosa Morros Pedrós.

CLINICAL STUDIES

  • Utilització de fàrmacs Insuficiència Cardíaca.  . 2022-2024. IP: Maria Giner Soriano.

  • Uso de fármacos en mujeres embarazadas y lactantes. Consecuencias en la salud de estas mujeres y en la de su descendencia. (SLT021/21/000068). Generalitat Catalunya. Departament de Salut. 2022 IP: Cristina Vedia Urgell.

  • Safety of Paxlovid during pregnancy (C4671037, VAC4EU & SIGMA study). Research Triangle Institute (RTI). 2023 IP: Maria Giner Soriano.

  • Safety of Paxlovid among patients with moderate or severe hepatic or renal impairment (C4671047, VAC4EU & SIGMA study). Research Triangle Institute (RTI). 2023 IP: Maria Giner Soriano.

  • Retrospective Longitudinal Study on Edoxaban in Patients with Non-Valvular Atrial Fibrillation in Europe. Syneos Health Consulting INC. 2021 IP: Maria Giner Soriano.

  • Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries. Research Triangle Institute (RTI). 2022-2025. IP: Maria Giner Soriano.

  • Post-Authorisation Safety Study of AZD1222. A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources. Research Triangle Institute - USA. IP: Maria Giner Soriano.

  • Post-Authorisation Safety Study of AZD1222. A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources. Research Triangle Institute (RTI). 2021 IP: Maria Giner Soriano.

  • Population-based study of the effectiveness of combined LAMA / LABA versus LABA / ICS therapy as maintenance treatment in COPD patients in primary care. Boehringer Ingelheim España, S.A. 2021 IP: Mònica Monteagudo Zaragoza.

  • Mild-moderate respiratory symptoms in patients with long-COVID-19: montelukast clinical trial and biological characterization (ESPERANZA COVID). (ICI21/00106). Instituto de Salud Carlos III. 2021-2025. IP: Rosa Morros Pedrós.

  • Incidencia y factores de riesgo de la Covid-19 en pacientes respiratorios crónicos. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021 IP: Mònica Monteagudo Zaragoza.

  • Hemorràgies majors en pacients tractats amb anticoagulants i interaccions farmacològiques: estudi cas-control amb dades de la història clínica d'Atenció Primària a Catalunya. 2023-2026. IP: Maria Giner Soriano.

  • Evaluation of the effectiveness of pregnancy prevention programme (PPP) for oral retinoids (acitretin, alitreinoin, and isotretionoin): a European before-after drug utilization study (DUS) using secondary data. IQVIA Technology and Services AG. 2019-2023. IP: Rosa Morros Pedrós.

  • Estudi d'utilització de medicaments per al tractament de la malaltia renal crònica. 2023 IP: Carles Vilaplana Carnerero.

  • Estudi descriptiu sobre la migranya. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2023 IP: Maria Giner Soriano.

  • Estudi de resultats en salut en diabetis mellitus tipus 2. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021 IP: Maria Giner Soriano.

  • Ensayo clínico doble ciego, aleatorizado, controlado con placebo, para evaluar la eficacia del complemento alimentario Manremyc® para evitar la infección por SARS-CoV-2. Laboratorio Reig Jofré, S.A. 2020-2024. IP: Rosa Morros Pedrós.

  • Desarrollo de un modelo predictivo de falta de adherencia terapéutica en el contexto del proyecto BEAMER. 2023-2026. IP: Maria Giner Soriano.

  • Comparación de la efectividad de fármacos en primera línea de tratamiento preventivo de la migraña en Atención Primaria: ensayo clínico pragmático. Estudio PREMI. (ICI23/00047). Instituto de Salud Carlos III. 2023-2026. IP: Maria Giner Soriano.

  • Características sociodemográficas, clínicas y farmacológicas asociadas con el pronóstico en pacientes con infección por SARS-CoV-2. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2020-2023. IP: Rosa Morros Pedrós.

Group publications

JOURNAL PUBLICATIONS

  • Fernández García S, Moreno AM, Giner Soriano M, Morros R, Ouchi D, García Sangenís A et al. Urinary Tract Infections in Men in Primary Care in Catalonia, Spain. Antibiotics-Basel. 2023;12(11): PMID:37998813.

  • Giner Soriano M, Prat Vallverdu O, Ouchi D, Vilaplana Carnerero C, Morros R. Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: A population-based cohort study in primary health care in catalonia. Front. Pharmacol. 2023;141110036-1110036. PMID:36825151.

  • Pericas C, Avcii G, Baena Díez JM, Domínguez A, Toledo D, Redondo A et al. Risk of partial school closure for COVID-19 by socio-economic level in the period 2020-22. J. Public Health. 2023;45(4):794-798. PMID:37291062.

  • Moleras Serra A, Morros Pedros R, Monteagudo M, Vedia Urgell C, Gomez Lumbreras A. Primary health care research in COVID-19: analysis of the protocols reviewed by the ethics committee of IDIAPJGol, Catalonia. BMC Prim. Care. 2023;24(1):91-91. PMID:37024845.

  • Carrasco Ribelles LA, Llanes Jurado J, Gallego Moll C, Cabrera Bean M, Monteagudo Zaragoza M, Violán C et al. Prediction models using artificial intelligence and longitudinal data from electronic health records: a systematic methodological review. J. Am. Med. Informatics Assoc. 2023;30(12):2072-2082. PMID:37659105.

  • de Homdedeu M, Sanchez Moral L, Violan C, Ràfols N, Ouchi D, Martín B et al. Mycobacterium manresensis induces trained immunity in vitro. iScience. 2023;26(6):106873-106873. PMID:37250788.

  • Ouchi D, Giner Soriano M, Vilaplana Carnerero C, Monfa R, Torres F, Morros R. Longitudinal treatment patterns in patients recently diagnosed with type 2 diabetes mellitus in Catalonia. Diabetes Res. Clin. Pract. 2023;202110777-110777. PMID:37321303.

  • Valles Fernandez R, Franzi Siso A, Garcia Vicente JA, Massot Mesquida M, Morales Navajas C, Pastor Ramon E et al. Implementation of a Centralized COVID-19 Vaccination Liaison Unit managed by Primary Care pharmacistpharmacologists. Pharm. Care Esp. 2023;25(1):7-18.

  • Ouchi D, Vilaplana Carnerero C, Monfa R, Giner Soriano M, Garcia Sangenis A, Torres F et al. Impact of Second-Line Combination Treatment for Type 2 Diabetes Mellitus on Disease Control: A Population-Based Cohort Study. Drugs - Real World Outcomes. 2023;10(3):447-457. PMID:37160557.

  • Giner Soriano M, Ouchi D, Vives R, Vilaplana Carnerero C, Molina A, Vallano A et al. Effectiveness and safety of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary healthcare in Catalonia. Front. Pharmacol. 2023;141237454-1237454. PMID:37781690.

  • Vázquez ML, Vilaplana Carnerero C, Gomez Lumbreras A, Prat Vallverdu O, Marsal JR, Urgell CV et al. Drug exposure during pregnancy in primary care: an algorithm and observational study from SIDIAP database, Catalunya, Spain. BMJ Open. 2023;13(8): PMID:37607789.

  • Moragas A, García Sangenís A, Llor C. Do external urine collection devices reduce contamination in urine samples for women with symptoms of urinary tract infection? A systematic review;. Enferm. Infec. Microbiol. Clin. 2023;41(7):426-429.

  • Moragas A, García Sangenís A, Llor C. Do external urine collection devices reduce contamination in urine samples for women with symptoms of urinary tract infection? A systematic review. Enferm. Infec. Microbiol. Clin. 2023;41(7):426-429. PMID:36707281.

  • Vellinga A, Luke Currier A, Garzon Orjuela N, Aabenhus R, Anastasaki M, Balan A et al. Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries. Antibiotics-Basel. 2023;12(3): PMID:36978439.

  • Moragas Moreno A, Fernández García S, Llor C, Ouchi D, García Sangenís A, Monteagudo M et al. Diagnostic and Therapeutic Management of Urinary Tract Infections in Catalonia, Spain: Protocol for an Observational Cohort Study. JMIR RES. Protoc. 2023;12PMID:36811950.

  • van der Velden AW, Shanyinde M, Bongard E, Böhmer F, Chlabicz S, Colliers A et al. Clinical diagnosis of SARS-CoV-2 infection: An observational study of respiratory tract infection in primary care in the early phase of the pandemic. Eur. J. Gen. Pract. 2023;29(1):2270707-2270707. PMID:37870070.

  • Marchal Torralbo A, Rodoreda Noguerola S, Perez Martín V, Bielsa Pascual J, Lizana Alcazo MT, Manresa Domínguez MJ et al. Bienestar emocional, percepciones y actitudes frente a la COVID-19 en adolescentes. Med. Fam.-SEMERGEN. 2024;50(3):102158-102158. PMID:38157749.

  • Zamora FJP, Barbero AM, Molinero A, Marcos NS, Lambert M, Taxis K et al. Auditoría de la dispensación de antibióticos en la farmacia comunitaria (proyecto 'Happy Patient'). Farm. Comunitarios. 2023;15(4):26-36.

  • Vilaplana Carnerero C, Giner Soriano M, Dominguez A, Morros R, Pericas C, Alamo Junquera D et al. Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review. Biomedicines. 2023;11(4): PMID:37189823.

PROCEEDING PAPERS

  • Pericas C, Baena Díez JM, Domínguez A, Toledo D, Redondo A, Vilaplana Carnerero C et al. Risk of partial closure of barcelona schools during the covid-19 pandemic according to socioeconomic level. Gac. Sanit. 2023;37257-258.

  • Gómez Lumbreras A, Vilaplana C, Leston VM, Vedia C, Giner Soriano M, Morros R. Hypertension and pregnancy: pharmacologic treatment and pregnancy outcomes. Value Health. 2023;26(6):252-253.

Anar a l'inici